Vectura Group plc Executive VP for Delivery Management Appointment
10 Febbraio 2020 - 8:00AM
RNS Non-Regulatory
TIDMVEC
Vectura Group plc
10 February 2020
Vectura announces the appointment of Sharon Johnson, Executive
Vice President for Delivery Management
New organisational structure to drive innovation, customer focus
and growth
Chippenham, UK - 10 February 2020: Vectura Group plc (LSE: VEC)
("Vectura" or "the Group") today announces a key appointment to
support innovation, customer focus and growth as the company
continues with its strategic development as a leading inhalation
specialist in the pharmaceutical services space.
Sharon Johnson has been appointed to the position of Executive
Vice President for Delivery Management, a newly-created leadership
role focussed on helping the company to transform into a successful
CDMO. In her new role, Ms. Johnson will build an end-to-end
approach to ensuring successful customer acquisition and programme
management, as well as managing the regulatory affairs and medical
affairs departments. She joins the Group on 10(th) February.
Will Downie, CEO of Vectura, said, "Sharon has built an enviable
reputation as an exceptional leader in the pharmaceutical services
space and has a strong track record of transformational leadership,
talent development and execution excellence. Our new structure will
support growth and sharpen our focus on working with our clients to
bring more inhalation medicines to market."
Ms. Johnson added, "Having spent my entire career in the
healthcare arena, it is a true privilege to join Vectura, a company
with such a rich scientific heritage in the inhalation space. I
look forward to working with my colleagues on the executive
leadership team and wider business to help combine deep science and
agile processes that will accelerate the development of new and
exciting inhaled medicines for patients."
Ms. Johnson has more than thirty years of experience in the
pharmaceutical industry, and prior to joining Vectura has held a
number of executive positions, most recently as Senior Vice
President, Global Quality and Regulatory Affairs at Catalent, one
of the world's leading CDMOs. Earlier in her career, she held the
position of Vice President of Quality for GE Healthcare's Medical
Diagnostic Division, and worked in roles of increasing
responsibility for Baxter Healthcare and Sanofi Aventis.
Ms. Johnson holds a postgraduate Diploma in Industrial
Pharmaceutical Studies with Distinction from Brighton University
and a BS Honours degree in Biological Sciences/Microbiology from
North East Surrey College of Technology.
- Ends-
For more information, please contact:
Vectura Group plc
David Ginivan - VP Corporate Communications +44 (0)7471 352 720
Elizabeth Knowles - VP Investor Relations +44 (0)7767 160 565
Consilium Strategic Communications
Mary-Jane Elliott / Sue Stuart / David Daley +44 (0)20 3709 5700
About Vectura
Vectura is a provider of innovative inhaled drug delivery
services that enable partners to bring their medicines to patients.
With differentiated proprietary technology and pharmaceutical
development expertise, Vectura is one of the few companies globally
with the device, formulation and development capabilities to
deliver a broad range of complex inhaled therapies.
Vectura has ten key inhaled and eleven non-inhaled products
marketed by partners with global royalty streams, and a diverse
partnered portfolio of drugs in clinical development. Our partners
include Hikma, Novartis, Sandoz (a division of Novartis AG),
Mundipharma, Kyorin, GSK, Bayer, Chiesi, Almirall, and Tianjin
KingYork.
For further information, please visit Vectura's website at
www.vectura.com
Forward-looking statements
This press release contains forward-looking statements,
including statements about the commercialisation of products.
Various risks may cause Vectura's actual results to differ
materially from those expressed or implied by the forward looking
statements, including: commercial limitations imposed by patents
owned or controlled by third parties; dependence upon strategic
alliance partners to develop and commercialise products and
services; difficulties or delays in obtaining regulatory approvals
to market products and services resulting from development efforts;
the requirement for substantial funding to conduct research and
development and to expand commercialisation activities; and product
initiatives by competitors. As a result of these factors,
prospective investors are cautioned not to rely on any
forward-looking statements. We disclaim any intention or obligation
to update or revise any forward looking statements, whether as a
result of new information, future events or otherwise.
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
END
NRABUGDDIUGDGGR
(END) Dow Jones Newswires
February 10, 2020 02:00 ET (07:00 GMT)
Grafico Azioni Vectura (LSE:VEC)
Storico
Da Mar 2024 a Apr 2024
Grafico Azioni Vectura (LSE:VEC)
Storico
Da Apr 2023 a Apr 2024
